In a report released today, Matt Larew from William Blair maintained a Hold rating on Maravai Lifesciences Holdings (MRVI – Research Report).
Maravai LifeSciences (MRVI) shares drop 15% premarket as it postpones 2024 earnings release, citing year-end financial review.
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stock fell 15% after the company announced it is postponing its fourth quarter and full year 2024 earnings release and conference call. The life ...
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced ...
Maravai LifeSciences Holdings (NASDAQ:MRVI) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is -$0.04 (+95.0% Y/Y) and the ...
DENTSPLY SIRONA Inc. XRAY is scheduled to release fourth-quarter 2024 results on Feb. 27, before the opening bell. Stay up-to ...